Fluzone® Intradermal Quadrivalent Influenza Vaccine

Safety and immunogenicity of a quadrivalent intradermal influenza vaccine in adults

(2015) Geoffrey J. Gorse et al.   VACCINE

The challenge of vaccinating adults: attitudes and beliefs of the Canadian public and healthcare providers

(2015) D M MacDougall et al.   BMJ Open

Intradermal vaccination using the novel microneedle device MicronJet600: Past, present, and future

(2015) Yotam Levin et al.   Human Vaccines & Immunotherapeutics

Immunogenicity of intramuscular MF59-adjuvanted and intradermal administered influenza enhanced vaccines in subjects aged over 60: A literature review

(2015) Barbara Camilloni et al.   Human Vaccines & Immunotherapeutics

First-year results of the Global Influenza Hospital Surveillance Network: 2012–2013 Northern hemisphere influenza season

(2014) Joan Puig-Barberà et al.   BMC PUBLIC HEALTH

Cutaneous immunization: an evolving paradigm in influenza vaccines

(2014) Harvinder S Gill et al.   Expert Opinion on Drug Delivery

Microneedle patches: Usability and acceptability for self-vaccination against influenza

(2014) James J. Norman et al.   VACCINE

Cost-effectiveness analysis of universal influenza vaccination with quadrivalent inactivated vaccine in the United States

(2014) Karen M Clements et al.   Human Vaccines & Immunotherapeutics

The Burden of Influenza B: A Structured Literature Review

(2013) W. Paul Glezen et al.   AMERICAN JOURNAL OF PUBLIC HEALTH

Influenza Illness and Hospitalizations Averted by Influenza Vaccination in the United States, 2005–2011

(2013) Deliana Kostova et al.   PLoS One

Adverse events after Fluzone® Intradermal vaccine reported to the Vaccine Adverse Event Reporting System (VAERS), 2011–2013

(2013) Pedro L. Moro et al.   VACCINE

Intradermally-administered influenza virus vaccine is safe and immunogenic in healthy adults 18–64 years of age

(2013) Geoffrey J. Gorse et al.   VACCINE

Safety and immunogenicity of revaccination with reduced dose intradermal and standard dose intramuscular influenza vaccines in adults 18–64 years of age

(2013) Geoffrey J. Gorse et al.   VACCINE

Influenza cost and cost-effectiveness studies globally – A review

(2013) Samuel K. Peasah et al.   VACCINE

Intanza®9 µg intradermal seasonal influenza vaccine for adults 18 to 59 years of age

(2013) Isabel Leroux-Roels et al.   Human Vaccines & Immunotherapeutics

A Meta-analysis of intradermal versus intramuscular influenza vaccines: Immunogenicity and Adverse Events

(2012) Fawziah Marra et al.   Influenza and Other Respiratory Viruses

A randomized control trial comparing immunogenicity, safety, and preference for self- versus nurse-administered intradermal influenza vaccine

(2012) Brenda L. Coleman et al.   VACCINE

Seasonal influenza vaccine efficacy and its determinants in children and non-elderly adults: A systematic review with meta-analyses of controlled trials

(2012) Carlos A. DiazGranados et al.   VACCINE

Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine

(2012) Carrie Reed et al.   VACCINE

Current evidence on intradermal influenza vaccines administered by Soluvia™ licensed micro injection system

(2012) Giancarlo Icardi et al.   Human Vaccines & Immunotherapeutics

The rationale for quadrivalent influenza vaccines

(2012) Christopher S. Ambrose et al.   Human Vaccines & Immunotherapeutics

Acceptance of Intanza® 9 μg intradermal influenza vaccine in routine clinical practice in Australia and Argentina

(2011) Peter Eizenberg et al.   ADVANCES IN THERAPY

Intradermal delivery of vaccines: potential benefits and current challenges

(2011) JK Hickling et al.   BULLETIN OF THE WORLD HEALTH ORGANIZATION

Intradermal influenza vaccine and new devices: a promising chance for vaccine improvement

(2011) Filippo Ansaldi et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Fluzone®Intradermal vaccine: a promising new chance to increase the acceptability of influenza vaccination in adults

(2011) Filippo Ansaldi et al.   Expert Review of Vaccines

Adjuvants and alternative routes of administration towards the development of the ideal influenza vaccine

(2011) Paolo Durando et al.   Human vaccines & immunotherapeutics

Devices for intradermal vaccination

(2011) Elsa E. Kis et al.   VACCINE

Modeling the cost of influenza: the impact of missing costs of unreported complications and sick leave

(2010) Yiting Xue et al.   BMC PUBLIC HEALTH

Influenza epidemiology—past, present, and future

(2010) Philippe R. S. Lagacé-Wiens et al.   CRITICAL CARE MEDICINE

Intanza® 15 μg Intradermal Seasonal Influenza Vaccine

(2010) Sean T. Duggan et al.   DRUGS & AGING

Intanza®: a new intradermal vaccine for seasonal influenza

(2010) Robert L Atmar et al.   Expert Review of Vaccines

Perception and acceptance of intradermal influenza vaccination: Patient reported outcomes from phase 3 clinical trials

(2010) Camille Reygrobellet et al.   Human vaccines & immunotherapeutics

Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice

(2008) Jean-François Nicolas et al.   Expert Review of Vaccines

Intradermal Influenza Vaccine Administered Using a New Microinjection System Produces Superior Immunogenicity in Elderly Adults: A Randomized Controlled Trial

(2008) David Holland et al.   JOURNAL OF INFECTIOUS DISEASES

The Impact of Influenza on Working Days Lost

(2008) Martin Keech et al.   PHARMACOECONOMICS

Intradermal vaccine delivery: Will new delivery systems transform vaccine administration?

(2008) Paul Henri Lambert et al.   VACCINE